Daily FNArena News - Small Caps

PeopleIN’s strategic review failed to realise extra value, nor was a sale forthcoming, but brokers back the company’s decision to stay the course

A positive trial result could put a rocket on shares in Dimerix, reports Tim Boreham, but investors won’t know the answer until early 2024

Recent research on Dicker Data notes an improving distribution capability and potential synergies from recent acquisitions

Tim Boreham reports cancer treatment biotech Chimeric has struggled, but may yet have a sting in its tail

Brokers remain enthusiastic on the outlook for Life360 following first quarter results

Strong demand projections for nickel have put ASX-listed Nickel Industries on investors’ radar, but the company’s outlook is not risk-free

Brokers review first quarter results and pending regulatory approvals for Avita Medical

Brokers continue to rate Judo Capital highly despite looming macroeconomic headwinds

Tim Boreham reports a change in CEO has given cancer monitoring biotech Impedimed a new lease of life

The ASX-listed AI sector can be split between tech providers developing AI tools and non-tech companies using AI to improve their existing business